Differential Impacts of Endogenous Antioxidants on Clinical Symptoms and Cognitive Function in Acute and Chronic Schizophrenia Patients

被引:4
|
作者
Lin, Chieh-Hsin [1 ,2 ,3 ]
Li, Tin-May [4 ,5 ]
Huang, Yu-Jhen [4 ,5 ]
Chen, Shaw-Ji [6 ,7 ]
Lane, Hsien-Yuan [3 ,4 ,5 ,8 ,9 ,10 ]
机构
[1] Chang Gung Univ, Kaohsiung Chang Gung Mem Hosp, Dept Psychiat, Coll Med, Kaohsiung, Taiwan
[2] Chang Gung Univ, Sch Med, Taoyuan, Taiwan
[3] China Med Univ, Grad Inst Biomed Sci, Taichung, Taiwan
[4] China Med Univ Hosp, Dept Psychiat, Taichung, Taiwan
[5] China Med Univ Hosp, Ctr Addict & Mental Hlth, Taichung, Taiwan
[6] Mackay Mem Hosp, Dept Psychiat, Taitung Branch, Taitung, Taiwan
[7] Mackay Med Coll, Dept Med, New Taipei, Taiwan
[8] China Med Univ, Neurosci & Brain Dis Ctr, Taichung, Taiwan
[9] Asia Univ, Coll Med & Hlth Sci, Dept Psychol, Taichung, Taiwan
[10] China Med Univ Hosp, Dept Psychiat, Taichung, Taiwan
关键词
Antioxidants; cognitive functions; negative symptoms; positive symptoms; schizophrenia; SUPEROXIDE-DISMUTASE; OXIDATIVE STRESS; GLUTATHIONE-PEROXIDASE; NEUROCOGNITIVE DEFICITS; NEGATIVE SYMPTOMS; GLOBAL ASSESSMENT; SODIUM BENZOATE; 1ST-EPISODE; CATALASE; ASSOCIATION;
D O I
10.1093/ijnp/pyad040
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background Impaired antioxidant defense is implicated in the pathophysiology of schizophrenia, and superoxide dismutase (SOD), catalase (CAT), and glutathione (GSH) are 3 first-line endogenous antioxidants. Various cognitive functions decline differently during the schizophrenia course. The characteristic roles of the 3 antioxidants in clinical and cognitive profiles in acute and chronic phases of schizophrenia require study. Methods We recruited 311 patients with schizophrenia, including 92 acutely exacerbated patients who had been off antipsychotics for at least 2 weeks and 219 chronic patients who had been stable on medication for at least 2 months. Blood SOD, CAT, and GSH levels; clinical symptoms; and 9 cognitive test scores were measured. Results Blood CAT levels were higher in the acute patients than in the chronic patients, whereas SOD and GSH levels were similar to one another. Higher CAT levels were correlated with less positive symptoms, better working memory and problem solving in the acute phase, and less negative symptoms, less general psychopathology, better global assessment of function, and better cognitive function (in speed of processing, attention, problem solving) in the chronic period. Higher SOD levels were correlated with better global assessment of function in the acute phase and better speed of processing, working memory, and verbal learning and memory in the chronic period. GSH influenced neither clinical nor cognitive manifestations. Conclusions This study showed that blood CAT affected different clinical and cognitive domains between acute and chronic stages of schizophrenia, SOD influenced cognitive functions in chronic state, but GSH affected none. Further studies are needed to explore the underlying mechanisms.
引用
收藏
页码:576 / 583
页数:8
相关论文
共 50 条
  • [1] Association of empathy with clinical symptoms and cognitive function in chronic schizophrenia patients with and without suicide attempts
    Ma, Zheng
    Tian, Yang
    Li, Jiaxin
    Liu, Junyao
    Wang, Dong-Mei
    Zhang, Xiang-Yang
    [J]. EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE, 2024, 274 (6) : 1395 - 1404
  • [2] Association of empathy with clinical symptoms and cognitive function in Chinese chronic schizophrenia patients with and without deficit syndrome
    Liu, Junyao
    Tian, Yang
    Wei, Shuochi
    Wang, Wenjia
    Wang, Dongmei
    Zhou, Huixia
    Zhang, Xiang-Yang
    [J]. PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 2022, 119
  • [3] Longitudinal study of symptoms and cognitive function in chronic schizophrenia
    Hughes, C
    Kumari, V
    Soni, W
    Das, M
    Binneman, B
    Drozd, S
    O'Neil, S
    Mathew, V
    Sharma, T
    [J]. SCHIZOPHRENIA RESEARCH, 2003, 59 (2-3) : 137 - 146
  • [4] Differential effects of different antipsychotic drugs on cognitive function in patients with chronic schizophrenia
    Dong, Rui
    Yuan, Lian
    Yang, Yong
    Du, Xiang-Dong
    Jia, Qiufang
    Dillon, Brett A.
    Yu, Liling
    Zhang, Xiang Yang
    [J]. HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL, 2020, 35 (06) : 1 - 8
  • [5] Relationship of psychopathological symptoms and cognitive function to subjective quality of life in patients with chronic schizophrenia
    Tomida, Kenji
    Takahashi, Nagahide
    Saito, Shinichi
    Maeno, Nobuhisa
    Iwamoto, Kunihiro
    Yoshido, Keizo
    Kimura, Hiroyuki
    Iidaka, Tetsuya
    Ozaki, Norio
    [J]. PSYCHIATRY AND CLINICAL NEUROSCIENCES, 2010, 64 (01) : 62 - 69
  • [6] Effect of risperidone or blonanserin on cognitive function and psychotic symptoms in patients with acute phase schizophrenia
    Hori, H.
    Yamada, K.
    Kamada, D.
    Shibata, Y.
    Katsuki, A.
    Yoshimura, R.
    Nakamura, J.
    [J]. EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2013, 23 : S465 - S465
  • [7] Comparison of clinical symptoms and cognitive function before and after risperidone switching in schizophrenia patients
    Suzuki, H
    Morokawa, Y
    Inoue, Y
    Gen, K
    Ishizeki, K
    Takagi, H
    Aoba, A
    Suzuki, H
    [J]. INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2004, 7 : S397 - S397
  • [8] Changes in inflammatory parameters and antioxidants and their impact on clinical symptoms, including cognitive functions, in patients with schizophrenia - scoping review
    Nycz, Blanka
    Krysta, Krzysztof
    Krzystanek, Marek
    [J]. ARCHIVES OF PSYCHIATRY AND PSYCHOTHERAPY, 2024, 26 (02): : 58 - 72
  • [9] The Effect of Yijinjing on the Cognitive Function of Patients With Chronic Schizophrenia
    Gao, Hui
    Luo, Chao
    Tu, Si-Jing
    Lu, Ru-Ping
    Jiang, Lin-Na
    Qiao, Hui-Jun
    Lin, Qu
    Li, Ning-Ning
    Chen, Jian-Hua
    [J]. FRONTIERS IN PSYCHIATRY, 2021, 12
  • [10] Gender differences in cognitive function of patients with chronic schizophrenia
    Han, Mei
    Huang, Xu-Feng
    Chen, Da Chun
    Xiu, Mei Hong
    Hui, Li
    Liu, Haibo
    Kosten, Thomas R.
    Zhang, Xiang Yang
    [J]. PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 2012, 39 (02): : 358 - 363